Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Olema Pharmaceuticals $240 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public…
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective…
Antengene HK$2.79 billion IPO
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong…
Auna $300 million high-yield notes offering
Davis Polk advised Auna S.A.A. in connection with its Rule 144A/Regulation S offering of $300 million aggregate principal…
Kodiak Sciences $645 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $645…
China Biologic going-private transaction
Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China…
Five Prime Therapeutics $173 million follow-on offering
Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an…
Bristol Myers Squibb $7 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC…
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its…
Affimed $75 million SEC-registered at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering…